James Goodrich

2.5k total citations · 1 hit paper
32 papers, 1.8k citations indexed

About

James Goodrich is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, James Goodrich has authored 32 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Infectious Diseases, 18 papers in Virology and 9 papers in Epidemiology. Recurrent topics in James Goodrich's work include HIV Research and Treatment (18 papers), HIV/AIDS drug development and treatment (15 papers) and HIV/AIDS Research and Interventions (11 papers). James Goodrich is often cited by papers focused on HIV Research and Treatment (18 papers), HIV/AIDS drug development and treatment (15 papers) and HIV/AIDS Research and Interventions (11 papers). James Goodrich collaborates with scholars based in United States, United Kingdom and Italy. James Goodrich's co-authors include Howard Mayer, Roy M. Gulick, Elna van der Ryst, Nathan Clumeck, John F. Sullivan, Bonaventura Clotet, Jacob Lalezari, Michael W. Dunne, Andrzej Horban and Steve Felstead and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of the American College of Cardiology.

In The Last Decade

James Goodrich

30 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

2008 570 citations Roy M. Gulick, Jacob Lalezari et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James Goodrich United States	16	1.1k	1.1k	533	264	186	32	1.8k
Dominique Mathez France	12	1.7k 1.6×	1.4k 1.3×	646 1.2×	554 2.1×	260 1.4×	20	2.2k
Luca Meroni Italy	21	570 0.5×	627 0.6×	470 0.9×	316 1.2×	162 0.9×	48	1.5k
Kristin Gebhard United States	9	1.2k 1.1×	667 0.6×	270 0.5×	590 2.2×	129 0.7×	11	1.7k
Steven Schnittman United States	17	1.7k 1.6×	1.3k 1.2×	609 1.1×	722 2.7×	282 1.5×	22	2.2k
Kersten K. Koelsch Australia	20	1.3k 1.2×	1.1k 1.0×	365 0.7×	901 3.4×	264 1.4×	33	2.3k
Montserrat Plana Spain	21	1.1k 1.0×	835 0.8×	298 0.6×	631 2.4×	140 0.8×	60	1.7k
Wayne B. Dyer Australia	24	1.5k 1.4×	812 0.7×	493 0.9×	1.1k 4.2×	152 0.8×	52	2.3k
Erika Benko Canada	21	931 0.8×	584 0.5×	296 0.6×	831 3.1×	148 0.8×	41	1.6k
Catherine Rehm United States	26	2.2k 2.0×	1.6k 1.4×	524 1.0×	924 3.5×	496 2.7×	42	2.8k
A Venet France	21	1.0k 1.0×	644 0.6×	405 0.8×	658 2.5×	104 0.6×	40	1.7k

Countries citing papers authored by James Goodrich

Since Specialization

Citations

This map shows the geographic impact of James Goodrich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Goodrich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Goodrich more than expected).

Fields of papers citing papers by James Goodrich

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James Goodrich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Goodrich. The network helps show where James Goodrich may publish in the future.

Co-authorship network of co-authors of James Goodrich

This figure shows the co-authorship network connecting the top 25 collaborators of James Goodrich. A scholar is included among the top collaborators of James Goodrich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James Goodrich. James Goodrich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Noonan, Devon, Wendy K. K. Lam, James Goodrich, et al.. (2024). A case study of inclusion of rural populations in research: Implications for science and health equity. Clinical and Translational Science. 17(8). e13885–e13885. 2 indexed citations

Seeley, John R., Shireen L. Rizvi, Scott N. Compton, et al.. (2024). Assessing the implementation of suicide-focused treatments delivered in hybrid telemental health format in a real-world setting. Psychotherapy Research. 35(7). 1198–1212. 1 indexed citations

Tanabe, Paula, et al.. (2024). Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease. Pediatric Blood & Cancer. 71(7). e31017–e31017.

Henry, Timothy D., Arshed A. Quyyumi, Gary L. Schaer, et al.. (2016). THE FINAL RESULTS OF THE IXCELL-DCM TRIAL: TRANSENDOCARDIAL INJECTION OF IXMYELOCEL-T IN PATIENTS WITH ISCHEMIC DILATED CARDIOMYOPATHY. Journal of the American College of Cardiology. 67(13). 1447–1447. 1 indexed citations

Patel, Amit N., Timothy D. Henry, Arshed A. Quyyumi, et al.. (2016). Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. The Lancet. 387(10036). 2412–2421. 113 indexed citations

Gulick, Roy M., Gerd Fätkenheuer, William D. Hardy, et al.. (2013). Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 65(1). 78–81. 31 indexed citations

Vernazza, Pietro, Cunshan Wang, Anton Pozniak, et al.. (2013). Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes. 62(2). 171–179. 16 indexed citations

Lazzarin, Adriano, Giovanni Di Perri, Juan Sierra‐Madero, et al.. (2011). Maraviroc Can Improve Lipid Profiles in Dyslipidemic Patients with HIV: Results from the MERIT Trial. HIV Clinical Trials. 12(1). 24–36. 42 indexed citations

Ayoub, Ayman, James Goodrich, Jayvant Heera, et al.. (2010). Hepatic safety and tolerability in the maraviroc clinical development program. AIDS. 24(17). 2743–2750. 12 indexed citations

10.

Sierra‐Madero, Juan, Giovanni Di Perri, Robin Wood, et al.. (2010). Efficacy and Safety of Maraviroc Versus Efavirenz, Both With Zidovudine/Lamivudine: 96-Week Results From the MERIT Study. HIV Clinical Trials. 11(3). 125–132. 49 indexed citations

11.

Davis, John D., Frances Hackman, Drew Lewis, et al.. (2010). Safety and tolerability of lersivirine, a nonnucleoside reverse transcriptase inhibitor, during a 28-day, randomized, placebo-controlled, Phase I clinical study in healthy male volunteers. Clinical Therapeutics. 32(11). 1889–1895. 7 indexed citations

12.

Hardy, William D., Roy M. Gulick, Howard Mayer, et al.. (2010). Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2. JAIDS Journal of Acquired Immune Deficiency Syndromes. 55(5). 558–564. 61 indexed citations

13.

Asmuth, David M., James Goodrich, David A. Cooper, et al.. (2010). CD4+ T-Cell Restoration After 48 Weeks in the Maraviroc Treatment-Experienced Trials MOTIVATE 1 and 2. JAIDS Journal of Acquired Immune Deficiency Syndromes. 54(4). 394–397. 39 indexed citations

14.

Saag, Michael S., James Goodrich, Gerd Fätkenheuer, et al.. (2009). A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1. The Journal of Infectious Diseases. 199(11). 1638–1647. 108 indexed citations

15.

Gulick, Roy M., Jacob Lalezari, James Goodrich, et al.. (2008). Maraviroc for Previously Treated Patients with R5 HIV-1 Infection. New England Journal of Medicine. 359(14). 1429–1441. 570 indexed citations breakdown →

16.

Goodrich, James. (2007). 48-Week Safety and Efficacy of Maraviroc, a Novel CCR5 Antagonist, in Combination with Optimized Background Therapy (OBT) for the Treatment of Antiretroviral-Experienced Patients Infected with Dual/Mixed-Tropic HIV-1. 8 indexed citations

17.

Englund, Janet A., Robert B. Couch, Kenneth V. I. Rolston, et al.. (1997). Influenza Among Hospitalized Adults with Leukemia. Clinical Infectious Diseases. 24(6). 1095–1099. 93 indexed citations

18.

Goodrich, James. (1997). A Comparison of Cytomegalovirus and Community Respiratory Viruses in Immunocompromised Patients. The American Journal of Medicine. 102(3). 37–41. 6 indexed citations

19.

Whimbey, Estella, James Goodrich, & Gerald P. Bodey. (1995). Pneumonia in cancer patients. Cancer treatment and research. 79. 185–210. 7 indexed citations

20.

Sharkey, P. K., John R. Graybill, Michael G. Rinaldi, et al.. (1990). Itraconazole treatment of phaeohyphomycosis. Journal of the American Academy of Dermatology. 23(3). 577–586. 166 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact